Clinically, BCL-3 expression is negatively correlated with survival in CRC patients, where strong nuclear staining of BCL-3 observed in tissue microarrays was associated with reduced patient survival [18] and additionally shown to be independent of tumour stage [14]. This evidence concerns the gene BCL3 and neoplasm.